ArticleJTO clinical and research reports2026
Perioperative Pembrolizumab in Japanese Participants With Early-Stage NSCLC: Subgroup Analysis From KEYNOTE-671.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03425643 (A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Who cites it
1 citing paper in PubMed.
- Perioperative Durvalumab for Resectable NSCLC: Updated Outcomes for Japanese Patients in AEGEAN.Cancer science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The global KEYNOTE-671 (clinicaltrials.gov: NCT03425643) study demonstrated significantly improved survival with perioperative pembrolizumab plus neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in early-stage non-small-cell lung cancer (NSCLC). We present findings from Japanese participants from KEYNOTE-671. Methods: Eligible participants (≥18 y) with previously untreated stage II, IIIA, or IIIB (N2) NSCLC were randomized 1:1 to neoadjuvant pembrolizumab 200 mg or placebo plus cisplatin-based chemotherapy every 3 weeks for up to 4 cycles followed by surgery and adjuvant pembrolizumab or placebo for up to 13 cycles (approximately 9 mo). Primary endpoints were event-free survival (EFS) and overall survival (OS). Results: Among 82 participants enrolled in Japan, 39 were randomized to pembrolizumab and 43 to placebo. Median time from randomization to database cutoff (August 19, 2024) was 52.7 (range, 32.7-74.9) months. The 48-month EFS rates (95% confidence intervals [CIs]) were 60.3% (42.8%-74.0%) and 39.2% (24.8%-53.4%), respectively, and the EFS hazard ratio was 0.54 (95% CI: 0.29-1.02). For OS, 48-month rates (95% CIs) were 79.5% (63.1%-89.2%) and 68.9% (52.4%-80.7%), and the OS hazard ratio was 0.76 (95% CI: 0.33-1.78). Grade 3 or higher treatment-related adverse events occurred in 23 participants (59%) treated with pembrolizumab and 20 participants (47%) with placebo; there were no deaths due to treatment-related adverse events. Conclusions: Perioperative pembrolizumab plus neoadjuvant chemotherapy improved efficacy versus neoadjuvant chemotherapy alone and had manageable safety in Japanese participants enrolled in KEYNOTE-671, supporting the use of perioperative pembrolizumab in Japanese patients with early-stage NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.